We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Commentary: Case Report: Abdominal Lymph Node Metastases of Parathyroid Carcinoma: Diagnostic Workup, Molecular Diagnosis, and Clinical Management.
- Authors
Fanciulli, Giuseppe; Di Molfetta, Sergio; Dotto, Andrea; Florio, Tullio; Feola, Tiziana; Colao, Annamaria; Faggiano, Antongiulio; Albertelli, Manuela; Altieri, Barbara; Barrea, Luigi; Bottiglieri, Filomena; Campione, Severo; de Cicco, Federica; Dicitore, Alessandra; Ferone, Diego; Ferraù, Francesco; Grossrubatscher, Erika; Gallo, Marco; Giannetta, Elisa; Grillo, Federica
- Abstract
Notably, immunohistochemistry-assessed PD-L1 expression was found in 4/18 patients (22.2%) with histologically confirmed PC ([10]), thus suggesting that immune checkpoint blockade may have a rationale in the treatment of this type of tumours. As a further reason of interest, hypocalcemia due to immune-related hypoparathyroidism has been reported as a rare complication following anti-PD-1 therapy initiation in patients with non-parathyroid tumours ([23], [24]). Keywords: parathyroid carcinoma; immune checkpoint inhibitors; ipilimumab; nivolumab; pembrolizumab EN parathyroid carcinoma immune checkpoint inhibitors ipilimumab nivolumab pembrolizumab 1 3 3 06/23/21 20210618 NES 210618 Introduction In the issue of March 2021, Lenschow et al. reported the case of a 46-year-old woman with recurrent, programmed death-ligand-1 (PD-L1) negative, tumor mutational burden (TMB)-high parathyroid carcinoma (PC), who showed stable disease as her best response on imaging, and a three-fold drop in PTH after treatment with intravenous pembrolizumab ([1]).
- Subjects
LYMPHATIC metastasis; HYPOPARATHYROIDISM; IMMUNE checkpoint proteins; CYTOTOXIC T lymphocyte-associated molecule-4; MOLECULAR diagnosis; MELANOMA; PARATHYROID glands
- Publication
Frontiers in Endocrinology, 2021, Vol 12, p1
- ISSN
1664-2392
- Publication type
Article
- DOI
10.3389/fendo.2021.700806